Abstract
Aim to find new compounds with stronger anticonvulsant activity and lower neurotoxicity, a novel series of 6-substituted-pyrido[3,2-d]pyridazine derivatives was synthesized using furo[3,4-b]pyridine-5,7-dione as the starting material. We evaluated their anticonvulsant activity and neurotoxicity using by maximal electroshock (MES) and rotarod neurotoxicity (TOX) tests. The results showed that N-m-chlorophenyl-[1,2,4]triazolo- [4,3-b]-pyrido[3,2- d]pyridazin-6-amine (3) was the most potent anticonvulsant, with ED50 value of 13.6 mg/kg and protective index ( PI = TD50/ED50) values of 7.2 in the MES test. Compound N-m-chlorophenyltetriazolo[5,1-b]-pyrido[3,2-d]pyridazin-6-amine (19), exhibited significant anticonvulsant activity in maximal electroshock test with PI value of 13.4, which was safer than marketed drug carbamazepine.
Keywords: Pyrido[3, 2-d]pyridazine, anticonvulsant, maximal electroshock, neurotoxicity.
Graphical Abstract
Medicinal Chemistry
Title:Design, Synthesis of 6-Substituted-pyrido[3,2-d]pyridazine Derivatives with Anticonvulsant Activity
Volume: 11 Issue: 6
Author(s): Zheng-Qi Dong, Xiao-Mei Liu, Cheng-Xi Wei and Zhe-Shan Quan
Affiliation:
Keywords: Pyrido[3, 2-d]pyridazine, anticonvulsant, maximal electroshock, neurotoxicity.
Abstract: Aim to find new compounds with stronger anticonvulsant activity and lower neurotoxicity, a novel series of 6-substituted-pyrido[3,2-d]pyridazine derivatives was synthesized using furo[3,4-b]pyridine-5,7-dione as the starting material. We evaluated their anticonvulsant activity and neurotoxicity using by maximal electroshock (MES) and rotarod neurotoxicity (TOX) tests. The results showed that N-m-chlorophenyl-[1,2,4]triazolo- [4,3-b]-pyrido[3,2- d]pyridazin-6-amine (3) was the most potent anticonvulsant, with ED50 value of 13.6 mg/kg and protective index ( PI = TD50/ED50) values of 7.2 in the MES test. Compound N-m-chlorophenyltetriazolo[5,1-b]-pyrido[3,2-d]pyridazin-6-amine (19), exhibited significant anticonvulsant activity in maximal electroshock test with PI value of 13.4, which was safer than marketed drug carbamazepine.
Export Options
About this article
Cite this article as:
Dong Zheng-Qi, Liu Xiao-Mei, Wei Cheng-Xi and Quan Zhe-Shan, Design, Synthesis of 6-Substituted-pyrido[3,2-d]pyridazine Derivatives with Anticonvulsant Activity, Medicinal Chemistry 2015; 11 (6) . https://dx.doi.org/10.2174/1573406411666150313152925
DOI https://dx.doi.org/10.2174/1573406411666150313152925 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Elaboration and Validation of HPLC/DAD Method for Quality Control of Products Containing Cannabidiol
Current Pharmaceutical Analysis Early Detection of Epileptic Seizures in Sparse Domains
Neuroscience and Biomedical Engineering (Discontinued) Mossy Fiber Sprouting as a Potential Therapeutic Target for Epilepsy
Current Neurovascular Research New Anticonvulsant Agents
Current Topics in Medicinal Chemistry An Insight into the Role of Artificial Intelligence in the Early Diagnosis of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design Adeno-Associated Virus (AAV) Vectors in the CNS
Current Gene Therapy Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology ADP-Ribosyl Cyclase as a Therapeutic Target for Central Nervous System Diseases
Central Nervous System Agents in Medicinal Chemistry Herbal Medicine for Anxiety, Depression and Insomnia
Current Neuropharmacology Secondary Brain Injuries in Thalamus and Hippocampus after Focal Ischemia Caused by Mild, Transient Extradural Compression of the Somatosensori Cortex in the Rat
Current Neurovascular Research Molecular Structure of Ionotropic Glutamate Receptors
Current Medicinal Chemistry Fibromyalgia: The Prototypical Central Sensitivity Syndrome
Current Rheumatology Reviews Pediatric Catatonia: Updating An Old Syndrome in Young People
Current Psychiatry Reviews Brain Magnetic Stimulation in Animal Models: A Valuable Lesson for Clinical Applications
CNS & Neurological Disorders - Drug Targets Flavonoids as Natural Inhibitors of Jack Bean Urease Enzyme
Letters in Drug Design & Discovery Safety and Efficacy of Melatonin in Pediatric Migraine Prophylaxis
Current Drug Safety Potential Biomarkers with Plasma Cortisol, Brain-derived Neurotrophic Factor and Nitrites in Patients with Acute Ischemic Stroke
Current Neurovascular Research From Surface to Nuclear Receptors: The Endocannabinoid Family Extends its Assets
Current Medicinal Chemistry Zebrafish as a Platform for Studies on Seizures and Epilepsy
Current Psychopharmacology